Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Key papers
Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition

key papersKey paper

Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition

Japan's surgical society guideline for bile duct, gallbladder and ampullary cancer, the only major guideline with a section on preventive treatment.

Overview Connected5

Overview

Third English edition of the Japanese Society of Hepato-Biliary-Pancreatic Surgery guidelines, first issued in 2007 and revised in 2014. Thirty-one clinical questions cover six topics: prophylactic treatment, diagnosis, biliary drainage, surgical treatment, chemotherapy and radiation therapy, graded with GRADE as strong (14 recommendations) or weak (14), with three questions left without a recommendation.

GuidelineChanged practice181 citations

Authors

Nagino M, Hirano S, Yoshitomi H, et al.

Published

Journal of Hepato-Biliary-Pancreatic Sciences, 2021

Full text

doi:10.1002/jhbp.870 PubMed 33259690

Findings

31 clinical questions across six topics including prophylactic treatment.
14 strong and 14 weak recommendations; three questions with no recommendation.

What it means

Japanese surgeons operate on gallbladder cancer far more often than UK surgeons and their guideline addresses prevention (pancreaticobiliary maljunction, polyps) as a clinical topic, which Western guidelines do not.

Caveats

Surgical-society guideline; systemic therapy sections predate the immunotherapy trials.
Evidence for many surgical questions is retrospective.

Connected

Similar pages

Key paper
Systematic review of management of incidental gallbladder cancer after cholecystectomy
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer
Shares Prophylactic (preventive) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?
Shares Prophylactic (preventive) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Changes in gallbladder cancer mortality and hospital discharges due to preventive cholecystectomy in Chile
Shares Prophylactic (preventive) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Tumor location and concurrent liver resection, impact survival in T2 gallbladder cancer: a meta-analysis of the literature
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.
Key paper
Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tag gallbladder-evidence.

cancers

Ampullary cancer (ampulla of Vater)Biliary tract cancer (cholangiocarcinoma)Gallbladder cancer

terms

Prophylactic (preventive) cholecystectomy Radical (extended) cholecystectomy

ProvenanceLast edited 2026-09-24 · Jude Gomila · Gallbladder cancer roadmap, ideas, guideline and trial pa… · diff · file

Sources & links

J Hepatobiliary Pancreat Sci 2021
PubMed

gallbladder-evidence

Data

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Cancers

Gallbladder cancer
Biliary tract cancer (cholangiocarcinoma)
Ampullary cancer (ampulla of Vater)

Terms

Radical (extended) cholecystectomy
Prophylactic (preventive) cholecystectomy

Not yet reviewedNeeds expert (scientific) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/key-papers/paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021/)
All key papers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021.

WebMCP tools registered on this page: onco_search, onco_get_entity.